Diwakar Davar, MBBS, MSc, discusses how data from the phase I trial of TSR-022, an anti-TIM-3 monoclonal antibody, and TSR-042, an anti-PD-1 agent, impact the treatment of patients with both melanoma and lung cancer.
Diwakar Davar, MBBS, MSc, assistant professor of medicine and medical oncologist/hematologist at UPMC Hillman Cancer Center, discusses how data from a phase I trial of TSR-022, an anti-TIM-3 monoclonal antibody, and TSR-042, an anti-PD-1 agent, impact the treatment of patients with both melanoma and lung cancer.
PD-1 checkpoint inhibition has been dominant in the treatment paradigm, says Davar, as it produces significant responses in both disease settings. According to these data, this combination is both safe and efficacious in patients who are refractory to PD-1.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More